MTH1 protein can mitigate DNA damage which caused by reactive oxygen species through hydrolyzing oxidized deoxy-ribonucleoside triphosphate.MTH1 is highly expressed in various cancers, so as to maintain the viability of cancer cells.MTH1 is closely related to tumor associated genes such as microRNA,RAS gene and p53 gene.Moreover, MTH1 inhibitors can selectively suppress the proliferation of cancers,which is a potential new target in tumor therapy.

Objective To investigate the clinical efficacy and safety of reteplase(rPA)adminis-tration in treating acute deep venous thrombosis(ADVT)of lower extremity.Methods A total of 1 87 pa-tients with ADVT were randomly divided into two groups,with 85 patients in rapid intravenous dripping group and 1 02 patients in 24-hour venouspumping group.Their effects on limb swelling,thrombolysis,and complicationswere compared for analysis.Results The differences in the curative effectsof reducingswell-ingand thrombolysis effect between the two groups werenot significant(P >0.05).Thethrombolysis time in the 24-hour venouspumping group was shorter than that of the rapid intravenous dripping group [(4.76 ± 1 .56)days vs(6.56 ±0.83)days,P <0.05],indicating 24-hour venouspumping was more effective than rapid intravenous dripping.Complication incidence in the 24-hour venouspumping group was less than that of the rapid intravenous dripping group(3.90% vs 1 7.6%,P <0.05).Conclusion rPA is a goodvenous thrombolytic agentwith rapid effect in treating ADVT.The 24-hour venouspumping was more effective and safe than the rapid intravenous dripping.